LXS Stock Analysis: LANXESS Aktiengesellschaft | XETRA
Specialty Chemicals | XETRA, Germany | Market Cap: 1.268m EUR | 12M Return: -42.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.58M
Qual. Beats: 0
Rev. Trend: -93.1%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
LANXESS Aktiengesellschaft (XETRA: LXS) is a German specialty chemicals company headquartered in Cologne. Founded in 1863, the group develops, manufactures, and markets chemical intermediates, additives, and consumer protection products for customers worldwide, operating through three reporting segments: Consumer Protection, Specialty Additives, and Advanced Intermediates.
Its product portfolio spans material protection and disinfectant/hygiene solutions, flavors and fragrances, water and liquid purification technologies, precursors for agrochemicals and pharmaceuticals, as well as additives, lubricants, flame retardants, plasticizers, bromine derivatives, basic and fine chemicals, organometallics, and inorganic pigments. End markets include the energy, natural resources, industrial, nutrition, health, consumer goods, agriculture, animal health, construction, and mobility sectors.
As a specialty chemicals producer, LANXESS follows a business-to-business model, selling performance- and application-specific inputs to other manufacturers rather than undifferentiated commodity volumes. Companies in this GICS Materials sub-industry typically compete on formulation expertise, regulatory approvals, and customer-specific technical support, which supports higher margins per unit but ties results to the demand cycles of the downstream industries it supplies.
- Consumer Protection margins expand on specialty pricing
- European auto and construction weakness pressures additives volumes
- Envalior sale proceeds accelerate deleveraging and capital returns
| Net Income: -661.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA -1.15 > 1.0 |
| NWC/Revenue: 19.89% < 20% (prev 25.99%; Δ -6.10% < -1%) |
| CFO/TA 0.05 > 3% & CFO 349.0m > Net Income -661.0m |
| Net Debt (2.25b) to EBITDA (617.0m): 3.65 < 3 |
| Current Ratio: 1.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (86.3m) vs 12m ago 0.0% < -2% |
| Gross Margin: 19.65% > 18% (prev 21.07%; Δ -1.42% > 0.5%) |
| Asset Turnover: 63.14% > 50% (prev 66.86%; Δ -3.72% > 0%) |
| Interest Coverage Ratio: -4.07 > 6 (EBIT TTM -175.0m / Interest Expense TTM 43.0m) |
| A: 0.14 (Total Current Assets 2.68b - Total Current Liabilities 1.59b) / Total Assets 7.75b |
| B: -0.02 (Retained Earnings -141.0m / Total Assets 7.75b) |
| C: -0.02 (EBIT TTM -175.0m / Avg Total Assets 8.63b) |
| D: 0.82 (Book Value of Equity 3.49b / Total Liabilities 4.25b) |
| Altman-Z'' = 1.58 = BB |
| DSRI: 0.99 (Receivables 644.0m/760.0m, Revenue 5.45b/6.36b) |
| GMI: 1.07 (GM 21.07% / 19.65%) |
| AQI: 1.00 (AQ_t 0.39 / AQ_t-1 0.38) |
| SGI: 0.86 (Revenue 5.45b / 6.36b) |
| TATA: -0.13 (NI -661.0m - CFO 349.0m) / TA 7.75b) |
| Beneish M = -3.08 (Cap -4..+1) = AA |
As of July 09, 2026, the stock is trading at EUR 14.85 with a total of 464,730 shares traded. Over the past week, the price has changed by +1.30%, over one month by -2.37%, over three months by -15.28% and over the past year by -42.82%.
Current recommended Stop Loss: 13.90 (which is 6.4% or 1.3 ATR below the current price).
LANXESS Aktiengesellschaft has no consensus analysts rating.
P/E Forward = 14.5773
P/S = 0.2327
P/B = 0.3624
P/EG = 1.1165
Revenue TTM = 5.45b EUR
EBIT TTM = -175.0m EUR
EBITDA TTM = 617.0m EUR
Long Term Debt = 1.79b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 597.0m EUR (from shortTermDebt, last quarter)
Debt = 2.67b EUR (from shortLongTermDebtTotal, last quarter) + Leases 162.0m
Net Debt = 2.25b EUR (calculated: Debt 2.67b - CCE 415.0m)
Enterprise Value = 3.52b EUR (1.27b + Debt 2.67b - CCE 415.0m)
Interest Coverage Ratio = -4.07 (Ebit TTM -175.0m / Interest Expense TTM 43.0m)
EV/FCF = 103.6x (Enterprise Value 3.52b / FCF TTM 34.0m)
FCF Yield = 0.96% (FCF TTM 34.0m / Enterprise Value 3.52b)
FCF Margin = 0.62% (FCF TTM 34.0m / Revenue TTM 5.45b)
Net Margin = -12.13% (Net Income TTM -661.0m / Revenue TTM 5.45b)
Gross Margin = 19.65% ((Revenue TTM 5.45b - Cost of Revenue TTM 4.38b) / Revenue TTM)
Gross Margin QoQ = 19.01% (prev 17.98%)
Tobins Q-Ratio = 0.45 (Enterprise Value 3.52b / Total Assets 7.75b)
Interest Expense / Debt = 1.61% (Interest Expense 43.0m / Debt 2.67b)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = -131.2m (EBIT -175.0m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 1.68 (Total Current Assets 2.68b / Total Current Liabilities 1.59b)
Debt / Equity = 0.76 (Debt 2.67b / totalStockholderEquity, last quarter 3.49b)
Debt / EBITDA = 3.65 (Net Debt 2.25b / EBITDA 617.0m)
Debt / FCF = 66.32 (Net Debt 2.25b / FCF TTM 34.0m)
Total Stockholder Equity = 3.72b (last 4 quarters mean from totalStockholderEquity)
RoA = -7.66% (Net Income -661.0m / Total Assets 7.75b)
RoE = -17.77% (Net Income TTM -661.0m / Total Stockholder Equity 3.72b)
RoCE = -3.17% (EBIT -175.0m / Capital Employed (Equity 3.72b + L.T.Debt 1.79b))
RoIC = -2.02% (negative operating profit) (NOPAT -131.2m / Invested Capital 6.48b)
WACC = 3.69% (E(1.27b)/V(3.94b) * Re(8.92%) + D(2.67b)/V(3.94b) * Rd(1.61%) * (1-Tc(0.25)))
Discount Rate = 8.92% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 0.0 | Cagr: 0.0%
[DCF] Terminal Value 73.10% ; FCFF base≈80.8m ; Y1≈70.9m ; Y5≈57.2m
[DCF] Fair Price = N/A (negative equity: EV 918.9m - Net Debt 2.25b = -1.34b; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.22 | # QB: 0
Revenue Correlation: -93.14 | Revenue CAGR: -9.72% | SUE: -0.14 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.41 | Chg30d=+2.50% | Revisions=+0% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.66 | Chg30d=+1750.00% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=0.15 | Chg30d=-79.20% | Revisions=-50% | GrowthEPS=-86.9% | GrowthRev=+2.9%
EPS next Year (2027-12-31): EPS=0.46 | Chg30d=+3.95% | Revisions=+0% | GrowthEPS=+214.2% | GrowthRev=+1.4%
[Analyst] Revisions Ratio: -30% (up=2, down=5)